3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells


Background: Recent studies have shown that 3-deazaneplanocin A (DZNep), a well-known histonemethyltransferase inhibitor, disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, whileinhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer andglioblastoma. However, little is known about effects of DZNep on ovarian cancer cells. Materials and
Methods:We here therefore studied DZNep-treated A2780 ovarian cancer cells in vitro. Proliferation of ovarian cancercells under treatment of DZNep was assessed by MTT and apoptosis by flow cytometry. Cell wound healingwas applied to detect the migration. Finally, we used q-PCR to assess the migration-related gene, E-cadherin.
Results: DZNep could inhibit the proliferation of A2780 and induce apoptosis Furthermore, it inhibited migrationand increased the expression of E-cadherin (P<0.05).
Conclusion: DZNep is a promising therapeutic agent forovarian cancer cells, with potential to inhibite proliferation, induce apoptosis and decrease migration.